A (16:34)

Live streaming now known as the pioneer of Paso, Justin Vineyards and Winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend, Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinwine.com and use promo code money20 to receive 20% off your order for a limited time. Right now, there's a talented person out there who could take your company to the next level. Do you want to hope they see your job posts before your competitors or do you want to match with them with Indeed Sponsored Jobs? Here's how it works. Sponsored Jobs Boost your post for quality candidates so you can reach the exact people you want faster. And get this According to Indeed data, Sponsored Jobs posted directly on Indeed are 90% more likely to report a hire than non sponsored jobs. Plus, with Indeed sponsored Jobs, there are no monthly subscriptions or long term contracts. Join the 1.6 million companies that sponsor their jobs with Indeed. Listeners of this show will get a $75 sponsored job credit to help get your job the premium status it deserves. @ Indeed.com MadMoney just go to Indeed.com MadMoney right now. Terms and conditions apply. Hiring do it the Right Way with.

B (18:04)

Indeed. For the past few years, virtually every stock connected to AI and the data center has been joined at the hip and they steadily march higher together. But last month that changed. Over the past two weeks, it's become very obvious that Google's Gemini 3 is now the best of the chat bots, surpassing OpenAI's chat CBT. I know I've totally forsworn chat CBT for Gemini 3. I just find it more comprehensive and better, let's say, at interpreting things. The Gemini 3 improvement was very good news for Google and all the stocks connected to the AI efforts, but it also caused everything connected to OpenAI to get whacked. Didn't help that we've been hearing more and more worries about OpenAI's lavish spending commitments. I mean, come on, this is a company with $20 billion annual revenue run rate. What's going to exit with that? It might be on the hook for $1.4 trillion. So Google stock sort as did Broadcom, which helped make the custom processors that were used to train Gemini 3. Hey, same goes Celestic. Remember that 1 CLS, the contract manufacturer, and a couple similar networking equipment vendors. We don't talk much about Lumentum TTM technologies. At the same time, what we're calling the Open Air complex got hit, and That's Nvidia, Oracle, AMD, Microsoft, along with the data center operator Coreweave and SoftBank, the Japanese investment firm. The Google complex and the Open Air complex used to trade together, but now they started moving in opposite directions. The five stocks in the Google complex were all flat or positive in November, up nearly 18% on average. While the six names in this open AI complex, they were all in the red. They were down an average of 20, 23%. At the same time, we're starting to see another parallel contingent of haves and have nots. This one's the hyperscalers that have good balance sheets, leper scalers that have not good balance sheets. These are companies that have poured tens of even hundreds of billions of dollars into data centers. Think Alphabet, Microsoft, Amazon, better Oracle and some private firms like OpenAI itself and Elon Musk. On a smaller scale, we're seeing something similar similar with the smaller data center operators like Core Weave, Nibius. On Friday, a sales desk note circulated by Tony Pascarella. He's the global head of hedge fund coverage at Goldman Sachs. It broke down the two groups. He says that Alphabet, Metta, Microsoft and Amazon clearly have the capacity to keep spending like crazy on AI, while Oracle, Core Weave and Nebulous, well, they got balance sheets that are much more strained. Pascal points out that the outfits with stronger balance sheets have started performing much better than the ones with weaker balance sheets. We ran the numbers ourselves. The former group was up an average of 1% last month, while the balance sheet have nots were down nearly 32% on average. I mean, it's pretty obvious. That's the fulcrum. Hey, speaking balance sheets, now the Wall Street's getting worried about all the data center spending. Apple starting to look real smart preceding on seeing this whole time they were criticized for that. I don't know about that anymore. Like I've been saying, why should they sell out billions to build out all this infrastructure when any of the generative AI companies would happily pay them tens of billions to be the default chat bot for Apple's ecosystem? Apple's up over 3% in November. It's up over 13% year to date. Big multiple expansion. Now if I were imagining one of these chat bots, I was, and I was up against Gemini 3, I would be running to Apple with my checkbook in hand, hoping they would let me pay them to be the default AI site. But I think only Gemini 3 right now would rank as acceptable to Cupertino. So what we make of this data center divergence first in general I think is actually pretty healthy. I'm never going to root against higher stock prices. You may own one of these stocks, but there was always something unsettling about the entire cohort rallying in lockstep. Now that the investors starting to think a little more critically about which of these companies deserves to be winners, I consider that a good sign stock picking matters again. At the same time, I need to warn you about chasing these ideas. If you want to buy the Google complex names I just mentioned, you're probably a bit late. The gains from Gemini 3 already seem to be baked in quite a move. More importantly, last month showed us how quickly things can change in the space. While Gemini 3 has suddenly become the top dog in general, it's possible that one of the other contenders can make a breakthrough and leapfrog them just like they leapfrog Chat GPT. Hey, just today we learned there's this private AI company I've never heard of, Runway. It's created a new AI video model. It's supposed to be better than anything on the market. And who knows what chat GPT6 will look like. I mean, I'll check it out when it comes out. Maybe with the help of new GPUs from Nvidia, it'll be even more impressive than Gemini 3. And the moves we saw last month will have to reverse or at least moderate a bit. Long story short, if you want to keep betting on the data center, you need to be more alert to what's happening in the industry and more selective with with your stock picking. Finally, let's be careful not to paint with too broad a brush here. For example, Nvidia clobber last week last month on worries about newfound competition. Remember, it's also part of the so called Open Air complex, but let's not forget that Nvidia just reported a blowout set of numbers less than two weeks ago. With excellent guidance for the current quarter and broader market dynamics notwithstanding, Nvidia is still essentially sold out for its latest generation chips. Demand for these things will far exceeds supply. And don't forget what happened today when they announced the deal with Synopsis. Until everything changes or until the company stops being the average, the industry standard bearer for AI developers. You know I got a real hard time getting too negative Jon Jensen Wallace Company. You know that. Once again I say own in video, don't treat it. That is my takeaway. That said, I am concerned that OpenAI feels like a big unsolved mystery. Until we get some kind of resolution about the status of their a clear indication that they'll be good for the money they're committed to spend, or worse, a clear indication that they're not good for it, then we're going to see volatility for the stocks of companies that are most clearly linked and closely linked to them. Unfortunately, that does include Nvidia, which doesn't necessarily need Open Air, but it's on track to receive several hundred billions of dollars worth of revenue from them, either directly or indirectly over the next several years. That's assuming OpenAI can raise money to pay a bills, maybe has to come public and borrow even more money. I don't know. So here's the bottom line. Last month the AI data center stocks finally started trading independently. The Google Complex cohort roared while the Open Air complex got hammered. Meanwhile, the hyperscalers with great balance sheets held it much better than ones with strained balance sheets. Just keep in mind that things change very fast in the space. So what was true last month might not necessarily stay true this month or next year. That said, it's hard to go wrong betting on the companies with superior balance sheets. As for ChatGPT versus Gemini versus everyone else, that changed in a heartbeat. Bitmoney's back after the break. Coming up, there's always a bull market somewhere, and Kramer's revealing an under the radar sector that's been showing strong signs of life. Next on Fox one, you can string Fox's biggest moments live. Get out bigger. I can feel the sweat and I can smell it a little bigger. That was genius. Yeah, that's what we talking about. Fox 1. We live for live streaming now. Streaming is changing the way we watch live sports and your Internet connection can be the difference between catching the game winning touchdown as it happens or hearing about it from your neighbor's cheers. That's why Comcast is building the network of the future. Using cutting edge AI and edge computing technology, we're bringing fans closer to the action in stunning high definition with ultra low latency. It's not just fast, it's game changing. Learn more at comcastcorporation.com sports known.

A (25:49)

As the pioneer of Paso, Justin Vineyards and Winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend, Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message, icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinmind.com and use promo code MONEY20 to receive 20% off your order for a limited.

B (26:19)

Time. Last week just before Thanksgiving, I got the chance to speak with Agilent Techniques Technologies, that's an arms dealer to the life sciences industry. A long time ago this stock, known as letter A for its stock symbol, was a great growth vehicle. In the decade before COVID Agilent chart was just a thing of beauty. Then when the pandemic got rolling, the stocks were even higher. And ever since the pandemic receded, things got choppy for this one, but also for the entire industry. The life sciences companies had all the equipment they needed, so the whole group spent years in the doghouse. Lately though, the things just caught fire. Adams now more than 55% from its April lows and that interview with CEO Porig McDonnell on our show was very encouraging. The company had just reported a very solid quarter last Monday night with a 7% organic growth and he made me feel like the business is really turning around. Now some of that's company specific, but some of its industry wide McDonald's playing that they're seeing a big push for reassuring in life sciences manufacturing federal initiative along with the rise of novel types of medicine that require more hardware to produce. At the same time, the Trump FDA turns out to be a lot less disruptive, many on Wall street expected even with RFK Jr at the helm at Health and Human Services. That got me thinking. Maybe it's Time to circle back the rest of the group. I used to recommend these arms dealers to the life sciences cohort. Pretty regular deal. But then if they went out of style at the Wall street fashion show. But if Agilent's turning around, then the same should be true for its compadres. That's why tonight I want to walk you through the best players in the industry. Now first there's tried and true but lately trying Danaher DHR conglomerate that became more focused on life sciences diagnostics when it spun off its water and product quality testing business. As for Alto a couple of years ago, we own Dana for the Chapel Trust. I got to tell you it's been really frustrating for the past couple of years. Even though we bought it during the post Covid washout. Turns out that was early as the stock languished for a very long time. Lately though, Dana has been acting much better. It's up 31% from its Aprils, is up 25% from its more recent low in April. I'm sorry in September. Now get this, in late October in the middle of the stock market most recent rally, Danaher reported a strong quarter driven by solid growth numbers from the company's crucial bioprocessing division which have been so languishing they posted a small revenue beat with a solid 3% organic growth as well as large earnings beat while management really reiterated their full year sales and earnings forecast. That was enough to get the stock. I told you it's been just a hellhole. Get the stock moving higher. Look at Wall street expects Standard to put up its best growth in years in 2026 mid single digit revenue growth and high single digit single digit earnings growth. If they can hit those targets, I bet the stocks keeps running. I still like the stock for the Travel Trust but we bought some stock real low in this one and I'm thinking of trimming it if the Stock jumps another 10 points. But 10 could be a lot. Next there's the biggest player in the group and that's Thermo Fisher Scientific which does a bit of everything, selling big ticket equipment, consumables and services to companies all across the life sciences industry with a new focus on clinical research services followed by by the. That's because of an acquisition they made called PPD a few years ago. Thermo Fisher experienced one of the biggest declines in the group earlier this year, but its stock had a strong recovery since then. It is currently up more than 50% from its mid June lows. You know I feel particularly good about this thermal Fisher because, well, I got to speak with the CEO Mark Casper in late October. He told, he told an excellent story. This was right after the company reported good quarter, a healthy top and bottom line beat with management raising their full year forecast. Casper told us about strength across his businesses. Not only are his commercial and end markets doing great, but even previously tough areas like academia, which really shocked me given the way the government's been. Government itself and China, which has been terrible, were solid and growing in. Casper also called out the reassuring theme that Agilent mentioned last last time. At the same time, Thermo Fisher is also partnering with OpenAI to create new tools and technologies that the company hopes will help speed up the drug development process. A real world use for AI that costs. Well, it goes beyond cost savings. Plus some of the acquisitions Thermo Fisher made recently. They're starting to pay off. The company actually announced another deal a few days after that interview. They're paying nearly $9 billion to buy a company called Clario holdings, which will give them even more exposure to the clinical trial ecosystem. Putting it all together, Thermo Fisher feels like it's back to being the company that I love for so many years. I'm talking about since the show began. They're talking less about some inventory glut somewhere and more about the exciting technologies they're creating. It is such a pleasure to listen to that company now. Now I've got two more small life science arms dealers to round out things. First one's called Revenue. You might have seen that one trade that. That's the life science business that remained when Perkinelmer broke itself up about two and a half years ago. Perkinelmer sold its supplied food and enterprise services business to a private equity firm and that business took the Perkinelmer name with it. The remaining life sciences business, which remain publicly traded, was renamed Revenue. Now after a couple of years of disappointing results where the stock went nowhere, Revenue finally posted some better than expected numbers in October. October and management raised their full year earnings forecast. It was a good solid result from a company that hasn't really given us much in those recent years. And the stock's gotten some traction since then. Revenue is the cheapest of the group, with the stock selling for around 21 times this year's earnings estimates. Finally, please don't forget about one that was always my personal favorite, never owned it. For the Trust Waters Corporation, one of the quieter companies in the space that specializes in liquid chromatography and mass spectrometry, Trichometric Spectrometry now that stuff that you need to be able to do with life science things. For much of the past few years, Waters was holding up much better than the rest of the industry. But the stock got hit real hard earlier this year in part because the company announced a complex deal to merge with Beckton Dickinson's biosciences and diagnostics business back in July. The market didn't like the deal initially in water source stock plunge it was so hard to understand. Things didn't turn around though. Now the stocks up about 45% from its August lows. Now some of that's because Waters arguably reported the best quarter in the group about a month ago. Revenue up 8% on a constant currency basis. Along with a healthy earnings beat, management also gave a nice boost to their full year forecast. Now Waters is still tricky because of that Becton Dickinson biosciences deal. It's expected to close the first quarter of next year. But once that happens, I think it's going to be a much, much bigger player and really I think we loved on Wall Street. Here's the bottom line. If Agilents turning around then I have to believe the arms dealers, the life sciences industry can keep making a comeback. Now that includes Danaher, Thermo, Fisher Revdy and Waters Corp. Check them out. I think they're all worth a closer look. Let's go to Bob in Tennessee. Bob. Jim, thanks for the call. Sure. I really, I really have enjoyed your audiobook. Thanks. Thank you. Well, that took forever. We got it right. People, like people should get the audible. It's a lot more fun. It is Pfizer, is there any growth potential in 2026 or is it a straight dividend play? 2026? Yeah, there is. It's got a. They got a lot of irons in the fire. I think Dr. Borle is going to trace things out in January at the J.P. morgan Conference. I think you might like what you hear. So 6.8% yield until then I would hold on to it. That's my. I would hold on to it. Let's go to Sam in Pennsylvania. Sam. Jim, how are you? I'm good, Sam. What do you. What's, what's up? Good. So Jim, you know, health care has had a lot of relative outperformance and one of the companies in that sector I've been keeping an eye on is Regeneron. Stock is up 54% from its low this summer. So I'm curious if you think Regeneron can keep up the momentum? Yes, down 30 today. Well, that's a bit. Well, it's a 70750 stock. Now let me just tell you something. Regeneron's move has been quiet, but Len Schleifer has been telling me stay focused on what they're doing. They're doing a lot of good stuff. I lost sight of it. I shouldn't have this one and Amgen bother me. They happened without me and that was my bad and I glad you brought it to our attention. All right. I have to believe the dealers to the life sciences industry are making a comeback. So if I were you, I'd check out Dan and her DHR Thermo, Fisher, Revite and Waters Corporation. Now as much for Man Bunny From Enersis to Thredup, if you go in and you stump me on a stock, I always promise to revisit the story and give you my take. Tonight we're doing just that. Then I'm in the unique position of not only being a dollar sign represented by a man, but also a journalist. I'm just sharing how the current reporting cycle is chokehold over this market and I don't like it. It was talked about all day, so little contrarian view coming up. And Oil calls Rapid Fire. Tonight's issue of the Lightning Round. So stay with. Whenever I get a call about a company that I either don't know or or haven't been following lately, I always do some research and circle back to it. Now that we're back from Thanksgiving, I've got a lot of homework to catch up on. Back in late October, Steve and Arizona wanted to know about a company called Seal sq. That's L A E S for you home gamers. CLSQ was spun out of a Swiss cybersecurity company named Wise Key about two and a half years ago, and it built itself as a quantum computing oriented cybersecurity place. Basically, they've worked on technology that can protect you many years in the future when hackers have access to incredibly powerful quantum computing. Now, while there was a lot of interest in the stock at the time of the spin off In May of 2023, that quickly fizzled, stock falling almost 99% from its high in 2023 to its penny stock low in August of last year. Twelve months ago, CLSQ had a market capitalization of just over $10 million. Hey. But over the past year, the stocks caught fire along with the rest of the quantum cohort. Even though it's totally unprofitable and it's only on track to bring in 18 million in revenue this year, but now it's got a market cap of $733 million. In other words, this was a year of magical investing stock. And as I said before, the year of magical investing is over. No thank you. Next up also in late October, Jeff in California about Thredup, which is an online consignment store, one of the world's largest resale platforms for apparel, shoes and accessories. This one came public during the pandemic year bull market in early 2021, but its stock plunged 98% from its 2021 highs to its lows 30 months ago. Similar trajectory to the real real now it seems these stocks are hot again, at least the ones that are left fed UP rallied over 300% in the past year. Stocks started running late last year just after the election, which makes me think people are betting on it as a tariff play. The tariffs make new stuff more expensive, which makes resale products more enticing. Threat apps certainly moving in the right direction after a down year in 2024. Revenues growing again and they're on track to put up 19% growth this year. Their EBITDA has turned positive too. That said, the company still overall losing money and it's not expected to become profitable till 2028. Given this 9,28 million dollars market capitalization, I don't feel comfortable recommending this one as it's never turned to profits is coming public. Sadly this whole industry just, I don't know might not be that good. If you feel compelled to bet on something in this space and trust me, you really don't have to then I pick Etsy, the deepop parent of course as he's not particularly doing well either but at least they're making money and the stocks relatively cheap at 14 times this year's earnings estimates is better than it's just better. And Thredup next in early November, Jim in Florida asked about another consumer facing name. This was Dave and Buster's. Now this one actually knew but I want to do more research to see if there was an opportunity to come. But it was public then went private thinking public. David's in Buster stock has been struggling of late and Jim in Florida is wondering if maybe do for a kind of a Macy's style comeback. Still the numbers are not so hot. Dave and Buster's look set to get its third straight year of negative same store sales and its second consecutive year of declining earnings per share. The company's been doing so poorly that around this time last year their CEO had to resign after several months with an interim CEO. The board brought in an executive from Young Brands, Tarun Lal, who's rolled out a bunch of initiatives to turn things around. Bring back TV ads, changing the menu, decreasing promotions. But it's still too soon to tell if this stuff is working. We'll have a better idea when Dave and Buster reports it just next week. Here's what I'll say for Jim in Florida. Listen, I'm intrigued by the idea of Dave and Buster's turnaround. But with many consumers struggling and the company itself doing so poorly, I'm nervous about trying to get into stock ahead of the turn. Doesn't help that the balance sheet remains a mess. So for now I'm keeping an eye on David Busters watching. Maybe you got a potential turn, but at this point I think it's too early to put money. Finally, let's talk about the one I really like and that's called Enersis, which Sam in Pennsylvania asked about back on November 20th. And this is really interesting. The company's based in Reading, Pennsylvania, designs, manufactures and distributes industrial batteries. It's been around since the late 90s came public 21 years ago. Over the long run, Enersis has been a great growth stock, climbing up steadily for most of the past two decades. But this year in particular, stocks going into overdrive, up roughly 54% year to date. Why? Because energy looks to be a big winner from the AI data center theme. Anything can store electricity is doing big business right now. Now here's the real exciting thing about Energies. While the stocks had an excellent run over the past several months, it's still very cheap. Trading at just 14 times this year's earnings estimates and 12 times next year's numbers, this company has beaten expectations for 16 consecutive quarters. So I trust these estimates. In fact, when Analysis reported a month ago, that quarter was a thing of beauty. 6% organic sales growth, huge earnings beat. Management also raised its full year sales and its earnings forecast pretty significantly. And the stocks, well, let's just say it's been on fire ever since. Really the only negative thing that I can say about Enersys is that you're chasing the stock here after all these recent gains. You know, I mean, they're in the past, but I feel a lot more comfortable chasing when a stock's at 14 times earnings. So I would actually bless buying some enters right here right now and then if it drops, you can buy more and then hope for a market wide sell off. Nothing having to do with Anderson and get even bigger. Overall, I think Sam in Pennsylvania has a good one in Enersys. I was pleasantly surprised to find out this was definitely not a year of magical investing stock. Bottom line, I don't really care for this CLSQ or Thredup. I'm intrigued by the prospect of Dave and Buss return. Not ready to recommend it though. But Enersys, that looks real good at these levels. Bit money is back after coming up, Kramer takes your calls. And the sky's the limit. It's a fast fire lightning round. Next. Let me give you a quick reminder. The special offer is almost over. If you want to follow every market move I make, now's the moment to join my investing club. Don't wait, scan that QR code or head to cnbc.com kramerclub for access to our morning meetings and my charitable trust portfolio. And now it is time. It's time for the white round myself. Don't you cross the way. That's on my stamp. You play this out and then the lightning round is over. Are you ready, Ski? Dead on the light round. Came to the. Let's start with Matt in Texas. Matt. Hey, Jim, nice to talk to you. I'm just wondering about silver. Should I try hecla for silver? Ah, come on, let's stick with those shiny metal. Nico. Eagle was down a couple bucks today. I say all right, now we're going to Travis and Georgia. Travis, Booyah. Jim, I'm giving you a call tonight. Oh, yeah? Yes. I'm calling about an IPO stock that I got invested in and now just trying to figure out if I should should keep pouring money into it or pull out. And that is klarna. I saw the guy on TV today. Made a lot of sense. Sell it and buy it for him. Let's go to Joe in New Jersey. Joe. Hello, Mr. Kramer. Hey, Joe. How you doing, partner? What's going on? Fine. Nothing much. Getting ready for the holidays. I'm halfway through reading your book and so far it's fabulous. Fantastic. Did you get to that part where I talked. Never mind. Thank you, buddy. Come on, Joe, let's go to work. Let's go to work. Yeah. All right. With analysts raising their price target and off of its highs is Newmont Corporation to buy. I like Newmont now. I do like Agneco better, but Newmont is real, real good. And Joe, welcome back. Glad to have you on the show. And that ladies, ladies and gentlemen, conclusion of the Lightning Round. The Lightning Round is sponsored by Charles Schwab. Coming up, Kramer's got a bone to pick with a narrative around the health of the consumer. And he's drawing some conclusions with the holiday shopping season in full swing. Next. Before I got into money management, I was a journalist, first at the Tallahassee Democrat and then at the Los Angeles Herald examiner, like Liam Neeson in Taken. That's given me a very particular set of skills. I learned that the editor is always right. So when the editor had an agenda, my word, not hers, you followed it. Or you risk seeing your story turn on its head, perhaps even killed, if you didn't play ball when you're playing for dinner, my term for when you're writing for dear life, you end up going with a program even if you didn't agree. Now, these days I don't play for dinner, have it in ages. So I can say whatever I want as long as I have researched it and believe it to be true. But the dailies and the wires are staffed with people who have an agenda, including the editors and often the writers themselves. The truth can be an abstraction for some of these people. This matters because right now we're getting a ton of stories about how the consumer is in bad shape. As you can see from recent receipt weakness or stress, balance sheets, credit card defaults. Whatever metric they pick, the approach of the consumer as pitiful has grave, ominous implications. We obviously need a rate cut. Yet the feds and the feds about lower rates. Many companies could be impacted negatively by this top down analysis. Many investors see this stuff and immediately sell, sell, sell retailers and many other things. The problem is it might not be true. This kind of handiwork is what I call thesis reporting, meaning the writers got a thesis, the Hubble consumer and their job is to prove it, even if it means massaging the facts. Why do this? Because negativity sells papers. Unfortunately, this is a false narrative. I can give you hard aggregate numbers like how MasterCard says Black Friday was spending was up 4% more than 4%, which is a reasonable amount. All things considered. I could tell you that credit quality actually is surprisingly good. Or I could go company by company, which is really my specialty right now. I find that other than Burlington stores, every single retailer that's reported is doing better than expected. In some cases much better than Kohl's. The resurgence. The department store with Macy's about to report excellent numbers on on top of Kohl's. The ascendance of TJX and Wal Mart shoppers Now above the $85,100,000 set came to Costco's club members shows a new level of interest that barely existed before the sizable gains in share price for Best Buy was more than just noteworthy. The strength in the dollar stores is insane when you consider how badly that they've been hit by tariffs. Same goes with Williams, Sonoma, Wayfair, and most notably Gap, which shot the Life Sal. It's hard to believe that the consumer's in trouble when so many retailers are doing so well, even with the full brunt of the tariffs in effect. So what are we to make of all this? First, that hobble consumer thesis. You know what? It's wrong even if you consider the spike in buy now, pay later use. Second, let's flip it on its head. Despite tariffs, despite the University of Michigan consumer confidence survey showing negativity, things are actually pretty darn positive. Third, it stands to reason that the consumer's fine, given that jobs are still available and confidence in being employed means more than a survey response. It's very tough to think straight when thesis reporting dominates your head as well as the nation's trading desk. Think you must though, because if you base your investments on bad information, you're probably going to lose money. When in doubt, trust the facts, not the theory. I'd like to say, as always, bull market Summer. I promise I'm finding just for you right here, man Money. I'm Drew Kramer. See you.

A (48:12)

Tomorrow. All opinions expressed by Jim Cramer on this podcast are solely Kramer's opinions and do not reflect the opinions of CNBC, NBCUniversal or their parent company or affiliates, and may have been previously disseminated by Kramer on television, radio, Internet or another medium. You should not treat any opinion expressed by Jim Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Kramer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy and it should not be relied upon as such. To view the full Mad Money disclaimer, please visit cnbc.com madmoneydisclaimer welcome to.

B (48:55)

Walgreens. What can I help you with today? Hi, I need a last minute gift for a secret Santa. Something thoughtful, impressive. Not a.

A (49:01)

Fruitcake. We've got Ferrero chocolates, artisan coffees, even a spa kit. Any vibe you're going for Whatever.

B (49:08)

Says wow, this guy's great at giving.

A (49:10)

Gifts. How about this premium skincare gift.

B (49:12)

Set? Just needs a.

A (49:13)

Bow. Will look like you planned it weeks.

B (49:15)

Ago. Well, happy holidays, gifts, holiday decor and more. The holiday road is long. We're with you all the way Walgreens.